Key statistics
On Monday, Rhythm Pharmaceuticals Inc (1RV:STU) closed at 80.50, -18.27% below its 52-week high of 98.50, set on Dec 12, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 78.00 |
|---|---|
| High | 80.50 |
| Low | 78.00 |
| Bid | 81.00 |
| Offer | 81.50 |
| Previous close | 81.50 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 68.29m |
| Free float | 63.64m |
| P/E (TTM) | -- |
| Market cap | 6.33bn USD |
| EPS (TTM) | -3.11 USD |
Data delayed at least 15 minutes, as of Mar 02 2026.
More ▼
Announcements
- Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
- Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
- Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
- Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
- Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
- Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
- Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
- Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
- Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
- Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
More ▼
